Details of the Drug

General Information of Drug (ID: DM8BOFB)

Drug Name
ADP-A2M10
Indication
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Phase 1 [1]
Head and neck cancer 2D42 Phase 1 [1]
Melanoma 2C30 Phase 1 [1]
Non-small-cell lung cancer 2C25 Phase 1 [2]
Drug Type
CAR-T cell therapy
Cross-matching ID
TTD ID
DM38KC
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanoma-associated antigen 10 (MAGEA10) TT1VNVM MAGAA_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
2 Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
3 Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.